Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer

References

• Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 108:1100 - 5; http://dx.doi.org/10.1038/bjc.2013.31; PMID: 23422757
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000; 36:313 - 25; http://dx.doi.org/10.1046/j.1365-2559.2000.00847.x; PMID: 10759945
   PubMed Web of Science ®Google Scholar
• Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97:1841 - 8; http://dx.doi.org/10.1002/cncr.11335; PMID: 12673709
   PubMed Web of Science ®Google Scholar
• Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113:678 - 82; http://dx.doi.org/10.1002/ijc.20598; PMID: 15455388
   PubMed Web of Science ®Google Scholar
• Al Moustafa AE, Achkhar A, Yasmeen A. EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. [Schol Ed] Front Biosci (Schol Ed) 2012; 4:671 - 84; http://dx.doi.org/10.2741/S292; PMID: 22202084
   PubMedGoogle Scholar
• Hung CM, Kuo DH, Chou CH, Su YC, Ho CT, Way TD. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food Chem 2011; 59:9683 - 90; http://dx.doi.org/10.1021/jf2021489; PMID: 21806057
   PubMed Web of Science ®Google Scholar
• Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M. Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol 2009; 34:329 - 38; PMID: 19148466
   PubMed Web of Science ®Google Scholar
• Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 2011; 30:783 - 95; http://dx.doi.org/10.1038/emboj.2010.351; PMID: 21224849
   PubMed Web of Science ®Google Scholar
• Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223:14 - 26; PMID: 20049846
   PubMed Web of Science ®Google Scholar
• Yan D, Avtanski D, Saxena NK, Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 2012; 287:8598 - 612; http://dx.doi.org/10.1074/jbc.M111.322800; PMID: 22270359
   PubMed Web of Science ®Google Scholar
• Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Andó S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004; 279:19908 - 15; http://dx.doi.org/10.1074/jbc.M313191200; PMID: 14985328
   PubMed Web of Science ®Google Scholar
• Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008; 105:956 - 64; http://dx.doi.org/10.1002/jcb.21911; PMID: 18821585
   PubMed Web of Science ®Google Scholar
• Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012:809291; http://dx.doi.org/10.1155/2012/809291; PMID: 22295251
   PubMedGoogle Scholar
• Spina A, Di Maiolo F, Esposito A, D’Auria R, Di Gesto D, Chiosi E, Sorvillo L, Naviglio S. Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. [Landmark Ed] Front Biosci (Landmark Ed) 2013; 18:133 - 44; http://dx.doi.org/10.2741/4092; PMID: 23276914
   PubMed Web of Science ®Google Scholar
• Otvos L Jr., Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 2011; 47:1578 - 84; http://dx.doi.org/10.1016/j.ejca.2011.01.018; PMID: 21353530
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-08-2755; PMID: 19074892
   PubMed Web of Science ®Google Scholar
• Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003; 54:131 - 52; http://dx.doi.org/10.1146/annurev.med.54.101601.152156; PMID: 12525670
   PubMed Web of Science ®Google Scholar
• Rock CL, Pande C, Flatt SW, Ying C, Pakiz B, Parker BA, Williams K, Bardwell WA, Heath DD, Nichols JF. Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese. Clin Breast Cancer 2013; 13:188 - 95; http://dx.doi.org/10.1016/j.clbc.2012.12.002; PMID: 23375717
   PubMed Web of Science ®Google Scholar
• Al Moustafa A. Fasting inhibits human cancer progression via the epithelial-mesenchymal transition process: Important evidence unraveled. Clin Cancer Investig J 2012; 1:181 - 3
   Google Scholar
• Al Moustafa AE. Insulin-like growth factor-1 enhances mortality risk in women with breast cancer through epithelial-mesenchymal transition initiation. Clin Cancer Investig J 2013; 2:175 - 7
   Google Scholar